NVP AAK 980

Drug Profile

NVP AAK 980

Alternative Names: NVP-AAK-980

Latest Information Update: 11 Mar 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Osteoporosis therapies; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 11 Mar 2003 No development reported - Preclinical for Postmenopausal osteoporosis in Switzerland (unspecified route)
  • 17 Jan 2000 Preclinical development for Postmenopausal osteoporosis in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top